Hydroxycinnamic-acid / ROS Cancer Research Results

HCAs, Hydroxycinnamic-acid: Click to Expand ⟱

Features:

Hydroxycinnamic acid compounds (p-coumaric, caffeic acid (CA), ferulic acid) occur most frequently as simple esters with hydroxy carboxylic acids or glucose, while the hydroxybenzoic acid compounds (p-hydroxybenzoic, gallic acid, ellagic acid) are present mainly in the form of glucosides. https://www.sciencedirect.com/topics/chemistry/hydroxycinnamic-acid
Hydroxycinnamic acids (HCAs) are plant-derived phenolic acids (including caffeic, ferulic, p-coumaric, and sinapic acids) with documented antioxidant, anti-inflammatory (NF-κB↓), and context-dependent anticancer effects in cellular and preclinical models. Mechanistic themes include activation of the Nrf2/ARE antioxidant response, suppression of pro-inflammatory and survival pathways (such as NF-κB and PI3K/AKT), modulation of MAPK signaling, and downstream effects on cell-cycle, apoptosis, invasion, and angiogenesis. Oral exposure is influenced by rapid metabolism (phase II conjugates) and food matrix effects, which affects systemic bioavailability and translational relevance. Biological effects vary by specific hydroxycinnamic derivative and its conjugated/esterified form. (Caffeic acid ≠ ferulic acid ≠ sinapic acid)

-Ferulic acid and p‐coumaric acid are naturally occurring hydroxycinnamic acids found in many plant-based foods (such as whole grains, fruits, and vegetables)

CA showed pro-oxidant potential due to its ability to interact with metals like copper, inducing lipid peroxidation and causing DNA damage within tumor cells through either oxidation or covalent adduct formation.

Summary:
-HCAs are classically antioxidant
-Such as caffeic acid, ferulic acid, and sinapic acid (SA)
-May increase sensitivity to chemotherapy
-Bioavailability is problem. Formulation strategies (e.g., liposomal or encapsulated forms) are investigated to improve systemic exposure.
-Propolis has caffeic acid (Caffeic acid (0.639–4.172 mg/g propolis)
-SA at higher concentrations may acts as a potent pro-oxidant agent
-SA may act in collaboration with other chemotherapeutic agents to improve treatment sensitivity. -Co-administration of caffeic acid or CAPE with other anti-tumor compounds (e.g., gallic acid) has shown additive or synergistic effects in selected models
-Combination of caffeic acid and endogenous copper ions can result in oxidative damage
-Ferulic Acid (abundant in whole grains,popcorn): upregulate apoptotic protein and downregulate anti-apoptotic protein.upregulating (BAX), (p53), (CYCS) and downregulating (Bcl-2),

Major Hydroxycinnamic Acids and Their Main Mechanisms

Hydroxycinnamic Acid	Abbreviation	Major Sources	Main Mechanisms of Action	Cancer-Relevant Emphasis	Notes
Caffeic acid	CA	Coffee, fruits, vegetables, herbs; also released from chlorogenic acids	ROS modulation; NF-κB suppression; apoptosis induction; mitochondrial dysfunction in cancer cells; inhibition of migration and invasion; antioxidant activity in normal tissue	ROS ↑ or ↓ (context-dependent); BAX ↑; BCL-2 ↓; caspases ↑; NF-κB ↓; MMPs ↓	One of the better-studied HCAs. Can act as an antioxidant at physiological exposure but become pro-oxidant under selected high-concentration or metal-dependent conditions.
Ferulic acid	FA	Whole grains, bran, rice, wheat, oats, fruits, vegetables	Cell-cycle arrest; mitochondrial apoptosis; PI3K/AKT/mTOR suppression; NF-κB inhibition; NRF2 activation in normal tissue; inhibition of EMT, migration and invasion	p53 ↑; p21 ↑; cyclins/CDKs ↓; BAX ↑; BCL-2 ↓; PI3K/AKT/mTOR ↓; MMP-2/9 ↓	Probably the most broadly characterized HCA for anticancer signaling. Many direct cytotoxic effects occur at concentrations much higher than typical dietary plasma exposure.
p-Coumaric acid	p-CA	Cereals, tomatoes, peanuts, fruits, vegetables, wine	Antioxidant and redox modulation; apoptosis; cell-cycle suppression; inflammatory signaling inhibition; glycolytic suppression in selected models	ROS modulation; apoptosis ↑; NF-κB ↓; PKM2 ↓ and glycolysis ↓ in selected models	Frequently studied in combination with ferulic acid. Metabolic effects such as PKM2 suppression should not be assumed to be universal.
Sinapic acid	SA	Brassica vegetables, mustard, rapeseed, cereals	Antioxidant activity; ROS-mediated apoptosis at higher concentrations; inflammatory pathway suppression; mitochondrial apoptosis; modulation of MAPK signaling	ROS ↑ (high concentration) or ↓; mitochondrial apoptosis ↑; NF-κB ↓; MAPK modulation	Less extensively characterized than caffeic or ferulic acid. Strong antioxidant effects predominate in many non-cancer models.
Chlorogenic acid	CGA	Coffee, apples, pears, berries, potatoes	Antioxidant and NRF2-associated cytoprotection; inhibition of inflammatory signaling; modulation of AMPK, PI3K/AKT and apoptosis pathways; glucose-metabolism regulation	NF-κB ↓; PI3K/AKT ↓ (model-dependent); apoptosis ↑; ROS modulation; AMPK ↑	An ester of caffeic acid and quinic acid rather than a simple free HCA. Often treated separately because its absorption and metabolism differ substantially from caffeic acid.
Caffeic acid phenethyl ester	CAPE	Propolis	Potent NF-κB inhibition; ROS-mediated cancer-cell killing; mitochondrial apoptosis; suppression of proliferation, angiogenesis and invasion	NF-κB ↓; ROS ↑; BAX ↑; BCL-2 ↓; VEGF ↓; MMPs ↓	A caffeic-acid derivative rather than a simple dietary HCA. Its pharmacology is sufficiently distinct that it is usually best treated as a separate compound.
Rosmarinic acid	RA	Rosemary, basil, lemon balm, sage and other Lamiaceae herbs	Antioxidant and NRF2 activation; NF-κB inhibition; apoptosis; suppression of PI3K/AKT and EMT; anti-inflammatory signaling	ROS ↓ or ↑ (context-dependent); NRF2 ↑; NF-κB ↓; PI3K/AKT ↓; EMT ↓; apoptosis ↑	An ester containing caffeic-acid-related structures. Often considered a hydroxycinnamic-acid derivative rather than a simple HCA.
Isoferulic acid	IFA	Cimicifuga species and selected medicinal plants	Antioxidant activity; inflammatory signaling suppression; glucose-metabolism modulation; apoptosis and growth inhibition in limited cancer models	NF-κB ↓; ROS ↓; apoptosis ↑ (model-dependent)	Structural isomer of ferulic acid with substantially less cancer-specific evidence.
o-Coumaric acid	o-CA	Plants, cereals and some fruits	Antioxidant and antimicrobial effects; limited evidence for apoptosis and proliferation suppression	ROS modulation; proliferation ↓ (limited evidence)	Much less studied for cancer than p-coumaric acid.
m-Coumaric acid	m-CA	Minor constituent of various plants and foods	Antioxidant and redox modulation; limited anti-inflammatory and antiproliferative activity	ROS modulation; inflammatory signaling ↓ (limited evidence)	Cancer evidence is sparse compared with the para isomer.

Practical grouping: For a class-level Hydroxycinnamic Acid entry, the four core free HCAs are caffeic acid, ferulic acid, p-coumaric acid, and sinapic acid. Chlorogenic acid, rosmarinic acid, and CAPE are chemically related HCA derivatives but have sufficiently distinct pharmacokinetics and biological activity that they are often better maintained as separate database products.

Hydroxycinnamic acids — HCAs are a family of plant-derived phenolic acids characterized by a C6-C3 cinnamic-acid backbone bearing one or more hydroxyl/methoxy substituents. Major dietary HCAs include caffeic acid, ferulic acid, p-coumaric acid, and sinapic acid; chlorogenic acids and related esters are important dietary conjugates. HCAs are classified as non-flavonoid polyphenolic phenolic acids and occur widely in coffee, cereals, fruits, vegetables, herbs, and plant-derived foods. They are not a single pharmacologically uniform agent: caffeic acid, ferulic acid, p-coumaric acid, and sinapic acid can differ substantially in potency, redox behavior, metabolism, and molecular targets. Anticancer activity remains predominantly preclinical and should generally be attributed to the specific HCA rather than generalized to the entire class.

Primary mechanisms (ranked):

Redox modulation: antioxidant activity predominates physiologically, whereas selected HCAs can become pro-oxidant in tumor models, particularly at high concentrations or in the presence of transition metals such as Cu²⁺, producing ROS and oxidative DNA damage.
Apoptosis and mitochondrial death signaling: selected HCAs increase BAX/BCL-2 ratio, cytochrome-c release, caspase activation, and PARP cleavage in cancer models.
Cell-cycle and proliferative signaling suppression: modulation of p53/p21 and suppression of cyclins/CDKs can produce G0/G1, S, or G2/M arrest depending on compound and tumor model.
NF-κB and inflammatory signaling suppression: HCAs frequently suppress NF-κB-associated inflammatory and prosurvival signaling, including COX-2 and inflammatory cytokine pathways.
PI3K/AKT/mTOR and MAPK modulation: selected HCAs inhibit prosurvival PI3K/AKT/mTOR signaling and alter ERK/JNK/p38 signaling in a strongly model-dependent manner.
Migration, EMT and extracellular-matrix remodeling: reduced MMP-2/MMP-9, EMT signaling, migration and invasion are reported for several HCAs.
Metabolic suppression: ferulic acid plus p-coumaric acid has been reported to suppress PKM2-associated aerobic glycolysis; this is mechanistically interesting but should not yet be generalized to all HCAs.
NRF2/ARE antioxidant response (secondary): activation of NRF2, HO-1 and endogenous antioxidant systems is prominent in normal/stressed tissues and contributes to cytoprotection; in established cancer, NRF2 activation could theoretically be tumor-protective in some contexts.
Chemo- and radiosensitization (context-dependent): selected HCAs enhance chemotherapy- or radiation-induced tumor-cell killing experimentally, but evidence is compound- and model-specific rather than a demonstrated class-wide clinical effect.

Bioavailability / PK relevance: HCAs are absorbed from the gastrointestinal tract, but the parent aglycones undergo substantial intestinal, hepatic and microbiome metabolism, particularly glucuronidation, sulfation, methylation and hydrogenation. Circulating exposure therefore consists substantially of conjugated and microbial metabolites rather than unchanged parent compound. Food matrix, esterification and site of intestinal release materially alter exposure. Pharmacokinetic reviews indicate that systemic parent-HCA concentrations after dietary intake are generally in the submicromolar-to-low-micromolar range, with one recent systematic assessment reporting maximal blood concentrations around 0.4 µM for cinnamic-acid derivatives such as caffeic/ferulic acid in the datasets examined. Formulation approaches including nanoparticles and encapsulation are being investigated to increase exposure.

In-vitro vs systemic exposure relevance: Many reported direct anticancer effects use tens to hundreds of micromolar HCA concentrations. For example, ferulic acid produced IC50 values of approximately 300 µM in PC-3 and 500 µM in LNCaP prostate cancer cells. These concentrations greatly exceed typical circulating concentrations attainable from ordinary dietary exposure. Consequently, direct tumor-cell cytotoxicity demonstrated at high in-vitro concentrations should not be interpreted as evidence that dietary HCAs achieve equivalent systemic anticancer exposure. Metabolites, local gastrointestinal exposure, chronic signaling effects and specialized formulations may have different pharmacological relevance.

Clinical evidence status: Preclinical for cancer treatment. There is substantial cell-culture evidence and some animal-tumor evidence for individual HCAs, especially ferulic and caffeic acids, but no established HCA-class anticancer therapy and no convincing randomized human evidence demonstrating treatment of established cancer with isolated HCAs. Human studies more commonly concern dietary exposure, cardiovascular/metabolic effects, pharmacokinetics, skin photoprotection or complex HCA-containing foods/extracts. HCAs should therefore be classified as experimental/preclinical anticancer agents rather than clinical adjuncts.

Hydroxycinnamic Acid Cancer Mechanisms

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Redox balance and ROS	ROS ↑ or ↓ (dose-dependent) (context-dependent)	ROS ↓; oxidative injury ↓	P, R	Redox stress modulation	HCAs are generally antioxidants at physiological exposure but caffeic, sinapic and related HCAs can become pro-oxidant under selected conditions. Cu²⁺-dependent oxidative DNA damage is a documented mechanism and should not be generalized to normal dietary exposure.
2	Mitochondrial apoptosis	BAX ↑; BCL-2 ↓; cytochrome-c ↑; caspases ↑; apoptosis ↑	↔ (model-dependent)	R, G	Intrinsic and extrinsic apoptosis	Strongly represented in ferulic, caffeic and sinapic acid tumor-cell studies, typically at pharmacological in-vitro concentrations.
3	Cell-cycle checkpoints	p53 ↑; p21 ↑; cyclins ↓; CDK2/4/6 ↓; cell-cycle arrest ↑	↔	G	Cytostasis	Ferulic acid has experimentally increased TP53, CDKN1A and CDKN1B while suppressing several cyclins and CDKs; exact arrest phase varies with cell type.
4	NF-κB inflammatory and survival signaling	NF-κB ↓; COX-2 ↓; inflammatory signaling ↓	NF-κB ↓ (stress-dependent); inflammation ↓	R, G	Anti-inflammatory and prosurvival suppression	One of the more reproducible HCA-family signaling themes, although strength varies among individual derivatives.
5	PI3K AKT mTOR survival axis	PI3K ↓; AKT ↓; mTOR ↓ (model-dependent)	↔ or mTOR ↓ (context-dependent)	R, G	Growth and survival suppression	Reported particularly for ferulic and other individual HCAs; not sufficiently uniform to assign identical modulation to every member of the class.
6	Migration EMT and matrix remodeling	MMP-2 ↓; MMP-9 ↓; EMT ↓; migration ↓; invasion ↓	↔	G	Anti-invasive phenotype	Observed in breast, prostate, thyroid, pancreatic and other experimental cancer systems with selected HCAs.
7	MAPK signaling	ERK JNK p38 ↔ (context-dependent)	ERK JNK p38 ↔ (context-dependent)	P, R, G	Stress and proliferation signaling	Direction is highly dependent on derivative, concentration, duration and cell type; a fixed class-wide arrow is inappropriate.
8	PKM2 and aerobic glycolysis	PKM2 ↓; glycolysis ↓	↔	R, G	Metabolic growth restriction	Demonstrated particularly for combined ferulic acid plus p-coumaric acid through an lncRNA/PKM2-associated mechanism. This is not established as a universal HCA effect.
9	Angiogenesis signaling	VEGF ↓; angiogenesis ↓ (model-dependent)	↔	G	Anti-angiogenic activity	Preclinical evidence exists for selected HCAs and derivatives but is less central than apoptosis, redox and proliferation mechanisms.
10	NRF2 ARE antioxidant response	NRF2 ↑ or ↔ (context-dependent)	NRF2 ↑; HO-1 ↑; GSH systems ↑	R, G	Secondary antioxidant adaptation	Generally cytoprotective in normal tissues. NRF2 activation is not necessarily desirable in established tumors because persistent NRF2 signaling can support tumor stress resistance.
11	Chemosensitization	Drug sensitivity ↑ (model-dependent)	Normal-tissue toxicity ↓ in some models	G	Combination-treatment modulation	Reported with selected HCAs and specific anticancer agents. Evidence remains preclinical and cannot be generalized to chemotherapy as a whole.
12	Radiosensitization	Radiation sensitivity ↑ (model-dependent)	Radioprotection reported in other contexts	P, R, G	Radiation-response modulation	Ferulic acid has sensitized cervical cancer cells experimentally through enhanced oxidative damage, while antioxidant properties can be radioprotective in normal tissues.
13	Clinical Translation Constraint	Parent-compound exposure ↓; extensive conjugation ↑	Dietary exposure generally well tolerated	R, G	Bioavailability and dose limitation	Many anticancer experiments use approximately 10–500 µM concentrations whereas typical circulating dietary exposure is far lower and substantially metabolized. Human cancer efficacy has not been established.

TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr

Alzheimer’s disease: Hydroxycinnamic acids have preclinical neuroprotective relevance, particularly caffeic and ferulic acids. Reported mechanisms include suppression of Aβ-associated oxidative stress and neuroinflammation, enhancement of endogenous antioxidant defenses, modulation of CREB/neurotrophic signaling, and possible effects on amyloid- and tau-associated pathology. Evidence is primarily cellular and animal-based; convincing clinical evidence that isolated HCAs prevent or treat Alzheimer’s disease is lacking. Rapid metabolism, low parent-compound systemic exposure and uncertain brain exposure remain important translational constraints.

Hydroxycinnamic Acids in Alzheimer’s Disease

Rank	Pathway / Axis	Modulation	Primary Effect	Notes / Interpretation
1	Oxidative stress and NRF2	ROS ↓; NRF2 ↑; antioxidant defenses ↑	Neuroprotection	Consistent with caffeic- and ferulic-acid preclinical models; principally antioxidant/cytoprotective rather than direct disease modification established in humans.
2	Amyloid beta toxicity	Aβ toxicity ↓; associated neuronal injury ↓	Reduced amyloid-associated neurotoxicity	Caffeic acid has demonstrated protection in Aβ-induced mouse models.
3	Neuroinflammation	NF-κB-associated inflammation ↓; inflammatory mediators ↓	Reduced inflammatory neuronal injury	Supported mainly by cellular and animal studies.
4	CREB and neurotrophic signaling	CREB ↑; neuronal survival signaling ↑	Synaptic and neuronal support	Ferulic acid has been associated with CREB phosphorylation and broader neurotrophic signaling.
5	Tau pathology	Tau-associated pathology ↓ (model-dependent)	Potential cytoskeletal protection	Evidence is substantially weaker than for oxidative stress and Aβ-related mechanisms.
6	Clinical Translation Constraint	Brain exposure ↓; metabolism ↑	Limits therapeutic translation	No established HCA treatment for AD; oral bioavailability, extensive conjugation and BBB exposure remain unresolved for pharmacological use.

ROS, Reactive Oxygen Species: Click to Expand ⟱

Source: HalifaxProj (inhibit)

Type:

Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)
ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
• Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
• HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
• SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
• AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
• mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
• HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
• Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy

ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination


Item  ROS↑  NRF2  Condition  Mechanism Class  Remarks  

ROS">Piperlongumine
+++  ↓  [D][T]  ROS-dominant
Selective <span class="wphighlight">ROS</span> stressor, Prevents compensatory upregulation of NRF2, ie GSH↓



ROS">Shikonin
+++ ↓/± [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + glycolysis + GPX4 inhibition



ROS">Vitamin K3 (menadione)
+++ ↓ [D] ROS-dominant
Quinone redox cycler; toxicity limits use



ROS">Copper (ionic / nano)
+++ ↓ [Fe][F] ROS-dominant
Fenton-type redox chemistry



ROS">Sodium Selenite
+++ ↓ [D] ROS-dominant
Pro-oxidant, depletes GSH



ROS">Juglone
+++ ↓ [D] ROS-dominant
Strong quinone <span class="wphighlight">ROS</span> chemistry



ROS">Auranofin
+++ ↓ [D] ROS-dominant
TrxR inhibition → redox collapse



ROS">Photodynamic Therapy (PDT)
+++ 0 [L][O₂] ROS-dominant
Singlet oxygen is core cytotoxic mechanism



ROS">Radiotherapy / Radiation
+++ 0 [O₂] ROS-dominant
DNA damage largely via <span class="wphighlight">ROS</span>



ROS">Doxorubicin
+++ ↓ [D] ROS-dominant
Chemo; redox cycling + mitochondrial <span class="wphighlight">ROS</span>



ROS">Cisplatin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> contributes to DNA/protein damage



ROS">Salinomycin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated CSC toxicity



ROS">Artemisinin / DHA
++ ↓ [Fe][T] ROS-dominant
Iron-activated radical generation



ROS">Sulfasalazine
++ ↓ [C][T] ROS-dominant
Ferroptosis; xCT inhibition → lipid <span class="wphighlight">ROS</span>



ROS">FMD / fasting
++ ↓ [M][C][O₂] ROS-dominant
Metabolic stress → mitochondrial <span class="wphighlight">ROS</span>



ROS">Vitamin C (pharmacologic)
++ ↓ [Fe][D] ROS-dominant
Extracellular H₂O₂ at high dose



ROS">Silver nanoparticles
++ ± [F][D] ROS-dominant
<span class="wphighlight">ROS</span> common; selectivity unreliable



ROS">Gambogic acid
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Parthenolide
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + NF-κB suppression



ROS">Plumbagin
++ ↓ [D] ROS-dominant
Quinone <span class="wphighlight">ROS</span> driver



ROS">Allicin
++ ↓ [D] ROS-dominant
Thiol-reactive oxidative stress



ROS">Ashwagandha (Withaferin A)
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Berberine
++ ↓ [D][M] ROS-dominant
Mitochondrial <span class="wphighlight">ROS</span> induction



ROS">PEITC
++ ↓ [D][C] ROS-dominant
GSH depletion + <span class="wphighlight">ROS</span>



ROS">Methionine restriction
+ ↓ [M][C][T] ROS-secondary
Redox vulnerability increased; <span class="wphighlight">ROS</span> indirect



ROS">DCA
+ ± [M][T] ROS-secondary
<span class="wphighlight">ROS</span> via forced OXPHOS



ROS">Capsaicin
+ ± [D][T] ROS-secondary
Ca²⁺ stress → <span class="wphighlight">ROS</span>



ROS">Galloflavin
+ 0 [D] ROS-secondary
<span class="wphighlight">ROS</span> not primary driver



ROS">Piperine
+ ± [D][F] ROS-secondary
Weak <span class="wphighlight">ROS</span> induction



ROS">Propyl gallate
+ ↓ [D] ROS-secondary
Pro-oxidant at high dose



ROS">Scoulerine
+ ? [D][T] ROS-secondary
Sparse <span class="wphighlight">ROS</span> data



ROS">Thymoquinone
± ± [D][T] Dual redox
Antioxidant ↔ pro-oxidant switch



ROS">Emodin
± ± [D][T] Dual redox
Not cancer-exclusive



ROS">Alpha-lipoic acid (ALA)
± ↑ [D][M] NRF2-dominant
Antioxidant at low dose



ROS">Curcumin
± ↑/↓ [D][F] NRF2-dominant
Hormetic redox behavior



ROS">EGCG
± ↑/↓ [D][O₂] NRF2-dominant
Auto-oxidation artifacts common



ROS">Quercetin
± ↑/↓ [D][Fe] NRF2-dominant
GSH-dependent cycling



ROS">Resveratrol
± ↑ [D][M] NRF2-dominant
<span class="wphighlight">ROS</span> only at high dose



ROS">Sulforaphane
± ↑↑ [D] NRF2-dominant
Strong NRF2 activator



ROS">Lycopene
0 ↑ — Antioxidant
Consistently antioxidant



ROS">Rosmarinic acid
0 ↑ — Antioxidant
Primarily antioxidant



ROS">Citrate
0 0 — Neutral
Metabolic; not a <span class="wphighlight">ROS</span> agent

Scientific Papers found: Click to Expand⟱

1645-

HCAs,

Chapter 8 - Hydroxycinnamic Acids: Natural Sources, Biosynthesis, Possible Biological Activities, and Roles in Islamic Medicine

Review,

Nor,

Dose∅, ROS⇅, Dose∅,

1643-

HCAs,

Mechanisms involved in the anticancer effects of sinapic acid

Review,

Var,

*BioAv↓, *toxicity↓, Dose∅, ROS⇅, ROS↑, Igs↑, TumCCA↑, TumAuto↑, eff↑, angioG↓, TumCI↓, TumMeta↓, EMT↓, Vim↓, MMP9↓, MMP2↓, Snail↓, E-cadherin↑, p‑Akt↓, GSK‐3β↓, TumCP↓, ChemoSen↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1, Dose∅, 3, eff↑, 1,
Total Targets: 20

Pathway results for Effect on Normal Cells:

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,

Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,
Total Targets: 2

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:95  Target#:275  State#:%  Dir#:3
  wNotes=0  sortOrder:rid,rpid

Hydroxycinnamic-acid / ROS Cancer Research Results

Major Hydroxycinnamic Acids and Their Main Mechanisms

Hydroxycinnamic Acid Cancer Mechanisms

Hydroxycinnamic Acids in Alzheimer’s Disease

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

Cell Death(tgid=5) ⓘ

Autophagy & Lysosomes(tgid=9) ⓘ

Cell Cycle & Senescence(tgid=11) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Pathway results for Effect on Normal Cells:

Drug Metabolism & Resistance(tgid=21) ⓘ

Functional Outcomes(tgid=23) ⓘ

Home Page